BioAtla (BCAB)

• Market cap: $12.5M
• 1 day: 7.87%
• 5 days: -4.8%
• 1 month: -1.06%
• 3 months: -78.87%
• 6 months: -73.05%
• Year to date: -68.44%
• 1 year: -53.04%
• 5 years: -99.75%
• 10 years: -99.46%
• Sector: Healthcare
• Industry: Biotechnology

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 61